Pfizer CentreOne Releases First Green-Chemistry-Driven API
The new progesterone active pharmaceutical ingredient, used captively by Pfizer for the past four years, reduces carbon footprint by more than 70%
Pfizer CentreOne, a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), has introduced Enviero progesterone to its contract customers. The API is made via a proprietary synthesis that significantly reduces waste, greenhouse gas emissions, and the use of hazardous solvents.
Overall, the process reduces overall carbon footprint by more than 70%, and eliminates the use of metal catalysts, according to the company. The process took more than 12 years to develop and uses a biocatalytic process based on plant sterols.
While Enviero is new to Pfizer CentreOne customers, Pfizer has used the compound as an intermediate for the past four years, and more than 500 metric tons have been manufactured to date for captive use. The compound, made exclusively at Pfizer’s Kalamazoo, MI, facility, is the first API to be launched from Pfizer CentreOne’s green-chemistry program.
Source: Pfizer CentreOne
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
